Stanton Elzi, MD
Internal Medicine · Wheat Ridge, CONPI 1417035502
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 676 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 676 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- GSK$947
- Boehringer Ingelheim$891
- Johnson & Johnson$799
- AstraZeneca$789
- plus $6K from 44 others
Across 596 payments — averaging $15,479 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$3.5M
- Modernatx, Inc.$2.6M
- Pfizer$948K
- Johnson & Johnson$677K
- Merck$497K
- Vertex$228K
- plus $743K from 8 others
What the payments were for
- Food & beverage$11,187100%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$11,220 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 162 | $182,341 |
| JardianceEmpagliflozin | 61 | $95,065 |
| XareltoRivaroxaban | 67 | $85,065 |
| OzempicSemaglutide | 48 | $68,766 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $43,602 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 141 | $43,137 |
| MyrbetriqMirabegron | 40 | $38,613 |
| MounjaroTirzepatide | 15 | $35,181 |
| FarxigaDapagliflozin Propanediol | 17 | $26,265 |
| JanuviaSitagliptin Phosphate | 18 | $25,163 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $8,717 |
| Levothyroxine Sodium | 709 | $8,238 |
| BelsomraSuvorexant | 11 | $7,615 |
| SteglatroErtugliflozin Pidolate | 13 | $7,243 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $730 | $182,341162 claims |
| Boehringer IngelheimJardiance | $891 | $95,06561 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $947 | $91,813210 claims |
| Johnson & JohnsonXarelto | $799 | $85,06567 claims |
| Novo NordiskOzempic | $1,103 | $68,76648 claims |
| MerckJanuvia, Belsomra, Steglatro | $288 | $40,02142 claims |
| Astellas Pharma US IncMyrbetriq | $217 | $38,61340 claims |
| Lilly USA, LLCMounjaro | $762 | $35,18115 claims |
| AstraZenecaFarxiga, Symbicort | $789 | $32,73734 claims |
| Sanofi-aventis U.S. LLCLantus | $80 | $6,32729 claims |
| AbbVieSynthroid | $1,105 | $4,73782 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Wheat Ridge
- William AllanWheat Ridge$13K
- Crystal CulbertWheat Ridge$8K
- Gilad GordonBoulder$476K
- Kathryn PolovitzParker$403K
- Monica GrafalsAvon$401K
- Luke WebbColorado Springs$287K
- Samuel PiedadColorado Springs$154K
- Sophia AmbrusoLittleton$62K
- Kristine KuhnAurora$61K
- Kenneth OleszekDenver$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.